“Analysts will be hard pressed to explain how equity markets ended unchanged on the day of an unprecedented policy announcement from the Fed. Rather than resort to cliches, they could consider the competing emotions felt by a patient taking an experimental drug that has not been through clinical tests. Let me explain.
The “expected and therefore fully priced in” excuse for an unchanged market does not work. A notable component of today’s Fed announcement – the shift to quantitative (employment and inflation) thresholds – was a surprise. Most had expected this would not occur until March 2013 at the earliest; and the few outliers had mostly opted for January.
The second traditional explanation – compensating news – also does not work. Away from the Fed, it was a relatively quiet day.
A better answer can be found by considering the competing emotions a patient feels when confronted with news of a new drug that is yet to go through clinical testing.
Professional investors welcomed the news that the Fed is “all in” when it comes to trying new drugs to stimulate the economy. And they fully understand that the transmission mechanism runs right through the equity markets. As Bernanke has stated, the Fed is looking to “push investors to take more risks.” Hence the initial positive reaction to the announcement.
Later in the day, however, and especially when Fed Chairman Ben Bernanke answered questions, the enthusiasm dissipated. There are reasons for this too.
As the day proceeded, investors realized that, like any experimental drug, there is a material risk of complications. After all, the Fed’s operational modalities are not straightforward; the analytical underpinnings are far from robust; and the Fed’s prior experimental measures have not succeeded in generating sustainable growth…”
If you enjoy the content at iBankCoin, please follow us on Twitter
